Dr Lal PathLabs and Metropolis fell up to 3% in early trade. Krsnaa Diagnostics slipped 2.2%, Thyrocare Technologies was down nearly 1%, and Suraksha Diagnostic dipped 0.5% on the BSE.
The pressure followed Amazon India’s announcement on Sunday about the rollout of Amazon Diagnostics, an at-home lab testing service that allows users to book tests, schedule and track sample collection, and access digital reports via the Amazon app.
The service, in collaboration with Orange Health Labs, will be available in Bengaluru, Delhi, Gurgaon, Noida, Mumbai, and Hyderabad, covering over 450 PIN codes.
Also Read: Why stock market is falling today? Key factors behind 900-point Sensex crash, Nifty below 24,850
Amazon has integrated this new offering with its existing health services — Amazon Pharmacy and Amazon Clinic — under the Amazon Medical banner.
“This expansion strengthens the foundation of Amazon Medical by building on the existing service of Pharmacy and Clinic. With Amazon Pharmacy, customers get access to a wide range of prescription medications and healthcare essentials, along with a free telemedicine consultation service and delivery benefits for Prime and non-Prime members. Amazon Clinic enables customers to consult licensed doctors for a range of primary healthcare needs through a seamless digital experience,” Amazon said.
Amazon Diagnostics will offer over 800 diagnostic tests and doorstep sample collection within 60 minutes.
Also Read: Is the grey market premium misleading? Decoding the valuation gap in HDB Financial’s IPO
The tech giant’s entry into diagnostics adds competition for established players, triggering investor concerns and weighing on stock prices.
Also Read: 11 Nifty mid & smallcap stocks that can rally 40-90% over the next 12 months
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)